© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
March 31, 2020
Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.
Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.
March 17, 2020
Empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.
March 12, 2020
Fish oil supplementation may be associated with lower all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events.
March 11, 2020
A new study found several shortcomings in blood pressure management.
February 26, 2020
The differences between antihypertension medication classes were generally small and nuanced in terms of their effect on reducing cardiovascular risks.
February 25, 2020
A secondary analysis presented at the American Stroke Association’s International Stroke Conference 2020 confirmed the safety of apixaban treatment.
February 24, 2020
Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.
February 12, 2020
Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.
February 06, 2020
A new study shows that patients who initiated treatment with blood pressure or cholesterol medications were more likely to reduce activity and gain weight.